- Home
- SIGA vs LYEL Comparison
SIGA vs LYEL Comparison
Compare SIGA & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$6.27
HOLD
Current Price
$22.27
Company Overview
Basic Information| Metric | SIGA | LYEL |
|---|---|---|
| Founded | 1995 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 486.2M | 490.1M |
| IPO Year | 2016 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SIGA | LYEL |
|---|---|---|
| Price | $6.27 | $22.27 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $25.00 |
| AVG Volume (30 Days) | ★ 354.2K | 95.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 9.42% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.40 | N/A |
| Revenue | N/A | ★ $61,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $132.36 | N/A |
| P/E Ratio | $15.90 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.95 | $0.39 |
| 52 Week High | $9.62 | $45.00 |
Technical Indicators
Market Signals| Indicator | SIGA | LYEL |
|---|---|---|
| Relative Strength Index (RSI) | 38.89 | 41.81 |
| Support Level | $6.10 | $21.27 |
| Resistance Level | $6.58 | $27.30 |
| Average True Range (ATR) | 0.23 | 2.12 |
| MACD | -0.06 | 0.05 |
| Stochastic Oscillator | 11.05 | 26.16 |
Price Performance
Historical Comparison SIGA
LYEL
About SIGA SIGA Technologies Inc.
SIGA Technologies Inc is a commercial-stage pharmaceutical company focused on the health security market. The company's main product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by the variola virus. The company derives maximum revenue from United States.
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.